TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06494280

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: programmed intermittent Bolus epidural analgesia
Description: About 30 minutes after the end of the epidural and administration of the loading dose, the woman will be asked to report her pain level. If the VAS score \<30, the woman will receive the study group protocol for pain maintenance, i.e., a programmed intermittent bolus of 10 ml of 0.1% bupivacaine and 2 μg/ml fentanyl every hour until the completion of labor and suturing of the incision. The participant can add to herself 5 ml of the same solution of Bupivacaine and Fentanyl every 30 minutes. The maximum dose that the parturient is allowed to receive is 20 ml for one hour.~If a breakthrough pain appears during labor, a bolus of 10 ml of anesthetic solution with the same concentration will be added.~Participants with a VAS score \>30 after 30 minutes of the loading dose will be asked to perform a new epidural (if it was decided that the epidural failed) otherwise her data will not be collected for the final analysis of the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: continuous epidural infusion
Description: About 30 minutes after the end of the epidural and administration of the loading dose, the woman will be asked to report her pain level. If the VAS score \<30, the woman will receive the control group protocol for pain maintenance, i.e., 0.1% Bupivacaine and 2 μg/ml fentanyl as a continuous infusion per one hour, until the delivery is completed, and laceration is sutured. The participant can add to herself 5 ml of the same solution of Bupivacaine and Fentanyl every 30 minutes. The maximum dose that the parturient is allowed to receive is 20 ml for one hour.~If a breakthrough pain appears during labor, a bolus of 10 ml of anesthetic solution with the same concentration will be added.~Participants with a VAS score \>30 after 30 minutes of the loading dose will be asked to perform a new epidural (if it was decided that the epidural failed) otherwise her data will not be collected for the final analysis of the study.
Study: NCT06405022

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: No intervention
Study: NCT05304910

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AG09222
Description: Lu AG09222 will be administered per schedule specified in the arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AG09222
Description: Lu AG09222 will be administered per schedule specified in the arm description.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to Lu AG09222 will be administered per schedule specified in the arm description.
Study: NCT00835887

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: low and high dose flavanoids
Description: treatment with flavanoid-rich or flavanoid-low cacao twice daily
Study: NCT06223698

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozole 2.5 mg daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: Letrozole 2.5 mg daily
Study: NCT04949880

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neurovascular Drug-Eluting Balloon Dilatation Catheter
Description: The neurovascular drug-eluting balloon dilatation catheter consists of a tip, a drug-coated balloon, markers, a catheter and a catheter hub. The main component of the drug coating is sirolimus, and the coating is evenly distributed on the effective length surface of the balloon.
Study: NCT06223698

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: Anastrozole 1 mg daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anastrozole
Description: Anastrozole 1 mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: Exemestane 25 mg daily
Study: NCT04987541

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intermittent theta burst stimulation
Description: stimulatory protocol
Study: NCT06223698

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exemestane
Description: Exemestane 25 mg daily
Study: NCT04987541

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: intermittent theta burst stimulation
Description: stimulatory protocol
Study: NCT05078333

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: dry needle
Description: dry needling (on 3 trigger points on the bilateral trapezius muscle) will applied to the other 36 randomly selected patients with an acupuncture needle with a size of 0.25x0.25 by the PMR specialist for a total of 6 sessions twice a week for 3 weeks.
Study: NCT06223698

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamoxifen
Description: Tamoxifen 20 mg daily
Study: NCT05078333

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: high intensity laser therapy
Description: High intensity laser therapy (HILT), one of the physical therapy methods, was approved by the FDA in 2002. Its beneficial and versatile effect has been proven in the treatment of many musculoskeletal diseases. In addition to the exercise program, randomly selected 36 case patients + HILT (BTL brand 6000 series, United Kingdom), to the cervical area, for the a period of 3 week-weekdays, 15-minute period and 15 sessions (1.02 minutes for each 25 cm² painful area, analgesic phase, with an anergy 8.0 W, a dose 5 J / cm², a frequency of 25 Hz and total 125 joules) will be applied.
Study: NCT06422351

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RP-L301
Description: Autologous genetically modified CD34+ hematopoietic stem cells containing the corrected PKLR (Pyruvate Kinase L/R) gene
Study: NCT05688579

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mineralocorticoid Receptor Antagonists(MRAs)
Description: Participants will be treated with mineralocorticoid receptor antagonists(MRAs) in addition to the original antihypertensive drugs for 48 months.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Blank control
Description: Participants will be treated with the original antihypertensive drugs for 48 months.
Study: NCT05250271

Intervention type: OTHER
Group type: OTHER
Intervention: 15 g dextrose
Description: 15 g dextrose tablets

Intervention type: OTHER
Group type: OTHER
Intervention: 15 g dextrose
Description: 15 g dextrose tablets

Intervention type: OTHER
Group type: OTHER
Intervention: 15 g dextrose
Description: 15 g dextrose tablets

Intervention type: OTHER
Group type: OTHER
Intervention: 15 g dextrose
Description: 15 g dextrose tablets
Study: NCT06006104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-4357 injection
Description: HRS-4357 injection
Study: NCT05955339

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NOTES
Description: The intervention will include: (1) a brief training on using the patient portal to access written visit information with assistance in setting up patient portal accounts where necessary (including strategies to share notes with a caregiver), (2) post-visit reminders to use the patient portal to access written visit information.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NOTES
Description: The intervention will include: (1) a brief training on using the patient portal to access written visit information with assistance in setting up patient portal accounts where necessary (including strategies to share notes with a caregiver), (2) post-visit reminders to use the patient portal to access written visit information.
Study: NCT05250271

Intervention type: OTHER
Group type: OTHER
Intervention: 15 g dextrose
Description: 15 g dextrose tablets
Study: NCT06223698

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: Tamoxifen 20 mg daily
Study: NCT05248204

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Scotchbond™ Universal Plus Adhesive
Description: Eligible tooth with Class I or Class II carious lesion randomized to the SBU+ treatment group will undergo restoration with Scotchbond™ Universal Plus Adhesive using self-etch mode and Filtek Universal Restorative

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Scotchbond™ Universal Adhesive
Description: Eligible tooth with Class I or Class II carious lesion randomized to the SBU control group will undergo restoration with Scotchbond™ Universal Adhesive using self-etch mode and Filtek Universal Restorative
Study: NCT05972525

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Shared decision-making supported by an in-consultation PtDA to patients with severe osteoarthritis in their hip or knee
Description: The intervention group has been involved in the development process of the PtDA. After receiving a training course in SDM and the use of a PtDA, the surgeons will practice SDM supported by an in-consultation PtDA during the consultations with the participant.
Study: NCT05250271

Intervention type: OTHER
Group type: OTHER
Intervention: 15 g dextrose
Description: 15 g dextrose tablets

Intervention type: OTHER
Group type: OTHER
Intervention: 5 g dextrose
Description: 5 g dextrose tablets

Intervention type: OTHER
Group type: OTHER
Intervention: 5 g dextrose
Description: 5 g dextrose tablets

Intervention type: OTHER
Group type: OTHER
Intervention: 5 g dextrose
Description: 5 g dextrose tablets

Intervention type: OTHER
Group type: OTHER
Intervention: 5 g dextrose
Description: 5 g dextrose tablets

Intervention type: OTHER
Group type: OTHER
Intervention: 5 g dextrose
Description: 5 g dextrose tablets

Intervention type: OTHER
Group type: OTHER
Intervention: 5 g dextrose
Description: 5 g dextrose tablets

Intervention type: OTHER
Group type: OTHER
Intervention: Protein bar
Description: 5 g carbohydrates + 10 g protein

Intervention type: OTHER
Group type: OTHER
Intervention: Protein bar
Description: 5 g carbohydrates + 10 g protein

Intervention type: OTHER
Group type: OTHER
Intervention: Protein bar
Description: 5 g carbohydrates + 10 g protein

Intervention type: OTHER
Group type: OTHER
Intervention: Protein bar
Description: 5 g carbohydrates + 10 g protein

Intervention type: OTHER
Group type: OTHER
Intervention: Protein bar
Description: 5 g carbohydrates + 10 g protein

Intervention type: OTHER
Group type: OTHER
Intervention: Protein bar
Description: 5 g carbohydrates + 10 g protein
Study: NCT05955339

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: AUDIO
Description: The intervention will include: (1) audio recording all visits with the study clinician for six months, (2) training on how to record visits and access visit recordings, and (3) post-visit reminders listen to the visit recordings.
Study: NCT06227949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luveris
Description: Patients will self-administer a subcutaneous injection of Luveris in addition to Gonal-F (FSH) daily until a pre-set criteria to trigger ovulation is reached.
Study: NCT06279806

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile health application use
Description: Women will be asked to use the app for at least 8 weeks. In order to monitor the usage, the researcher will monitor whether the women log in to the Information and Counseling section from the admin panel. Women who do not log in to the Information and Counseling section will be removed from the study at this stage. A weekly reminder will be sent to women via the mobile application. The questions asked by the participants through the question-and-answer section of the mobile health application will be examined every day and answered by the researcher between 10:00-11:00 every morning and 22:00-23:00 every evening. Likewise, the content shared by women in the forum section of the mobile application will be checked daily by the researcher and content that is harmful to women will be removed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Information of the breast cancer survivor period booklet
Description: Women in the control group will be given information of the breast cancer survivor period booklet.
Study: NCT04940871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Favipiravir HU 200 mg hard capsules
Description: Drug substance: Favipiravir Dose: 200 mg Administration: oral Formulation: capsules
Study: NCT05420571

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: digital impression
Description: 3D printed models after digital impressions

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: alginate impression
Description: Alginate impressions after plaster model infusion to make models
Study: NCT04155151

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 6 minute walk test
Description: A test of fitness that requests the participant to walk as far as they can at their own pace in 6 minutes, the distance walked in those 6 minutes is recorded.
Study: NCT03224247

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transverse cutting
Description: Transverse cutting and/or pulling.of lower uterine segment during lower cesarean section extending the uterine incision laterally.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: vertical splitting
Description: vertical splitting of lower uterine segment during lower cesarean section making the direction of traction up and downward instead of being laterally and we suppose that this will allow the tissues to split along their natural arrangement, decreasing the probability of extension of the wound into the uterine vessels, thus; decreasing blood loss; operative time and maternal recovery.
Study: NCT06332313

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: erector spina plane block
Description: ESP block is a method used to provide postoperative analgesia by injecting local anesthetic between the erector spinae muscle and the transverse process of the vertebra under ultrasound guidance, targeting the dorsal and ventral rami of thoracic and abdominal spinal nerves. The aim of this randomized controlled study is to observe whether there is a difference in tramadol consumption within 24 hours after surgery between patients who undergo RIRS operations at T11 level with different volumes of ESP blocks performed under ultrasound guidance before general anesthesia induction.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: erector spina plane block
Description: ESP block is a method used to provide postoperative analgesia by injecting local anesthetic between the erector spinae muscle and the transverse process of the vertebra under ultrasound guidance, targeting the dorsal and ventral rami of thoracic and abdominal spinal nerves. The aim of this randomized controlled study is to observe whether there is a difference in tramadol consumption within 24 hours after surgery between patients who undergo RIRS operations at T11 level with different volumes of ESP blocks performed under ultrasound guidance before general anesthesia induction.
Study: NCT05209828

Intervention type: DEVICE
Intervention: pfmmedical implantable vascular access ports
Description: Implantion of an implantable vascular access port which facilitates repeated vascular access intended for the delivery of medications, intravenous fluids, parenteral nutrition solutions or blood products and blood sampling using a Huber needle.
Study: NCT04658212

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 3D LCBDE
Description: three-dimensional (3D) video system for LCBDE (laparoscopic cholecystectomy and laparoscopic common bile duct exploration )

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ERCP
Description: Endoscopic retrograde cholangiopancreatography (ERCP)
Study: NCT05299333

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: High repetition muscle endurance and strengthening exercises Walking

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: High repetition muscle endurance and strengthening exercises Walking
Study: NCT05790928

Intervention type: DEVICE
Intervention: Lotrafilcon A spherical contact lenses
Description: CE-marked silicone hydrogel contact lenses indicated for the optical correction of refractive ametropia (myopia and hyperopia) in persons with minimal astigmatism that does not interfere with visual acuity

Intervention type: DEVICE
Intervention: Lotrafilcon A spherical contact lenses
Description: CE-marked silicone hydrogel contact lenses indicated for the optical correction of refractive ametropia (myopia and hyperopia) in persons with minimal astigmatism that does not interfere with visual acuity
Study: NCT04940871

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo HU
Description: Name: Placebo clinical sample Drug substance: placebo Dose: - Administration: oral Formulation: capsules
Study: NCT05366972

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasonographic measurements
Description: Posterior layers of the thoracolumbar fascia ,middle layers of the thoracolumbar fascia thickness and Lumbar interfacial triangle thickness~CSA (cross-sectional area) measurements of erector spinae muscles, quadratus lumborum muscles and the latissimus dorsi muscles
Study: NCT05022251

Intervention type: PROCEDURE
Intervention: Lumbar discectomy
Description: surgically removing a hernia
Study: NCT05734196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INZ-701
Description: Recombinant fusion protein that contains the extracellular domains of human ENPP1 coupled with an Fc fragment from an immunoglobulin gamma-1 (IgG1) antibody.
Study: NCT05482061

Intervention type: OTHER
Intervention: visual analog scale (VAS).
Description: The basic tool for pain intensity research was the VAS: 1) before and after anesthesia - at the stage of the medical and nursing brigade, military mobile hospital, military medical clinical center; 2) at the stage of the medical and nursing team - within 2 days; 3) at the stage of the military mobile hospital - within 5 days; 4) at the stage of the military medical clinical center - within 7 days, at the time of discharge from the hospital; 5) at the rehabilitation stage. Intervals between analgesia were also studied. The study of the neuropathic component of pain was carried out using the diagnostic DN4: military mobile hospital, a military medical clinical center, then at the time of discharge from a military medical clinical center. Study of the presence of an acute stress reaction - anamnesis + The Hospital Anxiety and Depression Scale. Satisfaction with treatment results was studied using the Chaban Quality of Life Scale.

Intervention type: OTHER
Intervention: visual analog scale (VAS).
Description: The basic tool for pain intensity research was the VAS: 1) before and after anesthesia - at the stage of the medical and nursing brigade, military mobile hospital, military medical clinical center; 2) at the stage of the medical and nursing team - within 2 days; 3) at the stage of the military mobile hospital - within 5 days; 4) at the stage of the military medical clinical center - within 7 days, at the time of discharge from the hospital; 5) at the rehabilitation stage. Intervals between analgesia were also studied. The study of the neuropathic component of pain was carried out using the diagnostic DN4: military mobile hospital, a military medical clinical center, then at the time of discharge from a military medical clinical center. Study of the presence of an acute stress reaction - anamnesis + The Hospital Anxiety and Depression Scale. Satisfaction with treatment results was studied using the Chaban Quality of Life Scale.
Study: NCT06228378

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Raman microspectroscopy
Description: Raman microspectroscopy is a non-destructive method for observing and characterising the molecular composition and external structure of a biological sample based on the phenomenon of inelastic light scattering (Raman effect).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Raman microspectroscopy
Description: Raman microspectroscopy is a non-destructive method for observing and characterising the molecular composition and external structure of a biological sample based on the phenomenon of inelastic light scattering (Raman effect).
Study: NCT05774717

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Description: 1 gram IV (intravenous) tranexamic acid administered in the operating room just prior to starting the case (10 minutes), at time that routine preoperative antibiotic is given.
Study: NCT06334419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gaboxadol
Description: Drug: Gaboxadol 10 mg as a single dose (two 5mg capsules)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Two placebo capsules
Study: NCT06092190

Intervention type: DEVICE
Intervention: EMG
Description: Electrodiagnostic testing (electromyography and nerve conduction velocity) can objectively verify the tibial nerve dysfunction. Electrodiagnosis rests upon demonstrating impaired tibial nerve conduction across the tarsal tunnel in context of normal conduction

Intervention type: DEVICE
Intervention: EMG
Description: Electrodiagnostic testing (electromyography and nerve conduction velocity) can objectively verify the tibial nerve dysfunction. Electrodiagnosis rests upon demonstrating impaired tibial nerve conduction across the tarsal tunnel in context of normal conduction
Study: NCT04773899

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Procedure : Multimodal microvascular assessment at study inclusion
Description: * Vascular occlusion test (VOT) performed on the arm. Measurement of the quality of tissue reperfusion by NIRS on the thenar eminence and the digital perfusion index.~* Microcirculation reactivity is measured for each patient with a laser speckle contrast imaging (LSCI) placed on the forearm. Tests will be performed for evaluation of microvascular reactivity: Acetylcholine and Nitroprusside Iontophoresis.~* Morphological analysis of the microcirculation by sublingual videomicroscopy.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Procedure : Multimodal microvascular assessment at study inclusion
Description: * Vascular occlusion test (VOT) performed on the arm. Measurement of the quality of tissue reperfusion by NIRS on the thenar eminence and the digital perfusion index.~* Microcirculation reactivity is measured for each patient with a laser speckle contrast imaging (LSCI) placed on the forearm. Tests will be performed for evaluation of microvascular reactivity: Acetylcholine and Nitroprusside Iontophoresis.~* Morphological analysis of the microcirculation by sublingual videomicroscopy.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Procedure : Multimodal microvascular assessment at study inclusion
Description: * Vascular occlusion test (VOT) performed on the arm. Measurement of the quality of tissue reperfusion by NIRS on the thenar eminence and the digital perfusion index.~* Microcirculation reactivity is measured for each patient with a laser speckle contrast imaging (LSCI) placed on the forearm. Tests will be performed for evaluation of microvascular reactivity: Acetylcholine and Nitroprusside Iontophoresis.~* Morphological analysis of the microcirculation by sublingual videomicroscopy.
Study: NCT05155111

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Telemedicine consult
Description: A joint assessment between Neonatologist at bedside and Neurologist by telemedicine will be performed to assess severity of neonatal encephalopathy